Suchresultate
Efluelda 0.7 ml, suspension injectable en seringue préremplie
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), Haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/9/2021 (H3N2)-like: reassortant virus SAN-010 derived from A/Darwin/9/2021), Haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: derived from B/Michigan/01/2021 (Victoria lineage)(wild type))
Unternehmen: Sanofi-Aventis (Suisse) SA
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), Haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/9/2021 (H3N2)-like: reassortant virus SAN-010 derived from A/Darwin/9/2021), Haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: derived from B/Michigan/01/2021 (Victoria lineage)(wild type))
Unternehmen: Sanofi-Aventis (Suisse) SA
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Fluarix Tetra 15 µg / 0.5 ml, Injektionssuspension
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus Stamm A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), Haemagglutininum influenzae A (H3N2) (Virus Stamm A/Darwin/9/2021 (H3N2)-like: reassortant virus IVR-227 derived from A/Darwin/6/2021), Haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant virus BVR-26 derived from B/Austria/1359417/2021 (Victoria lineage))
Unternehmen: GlaxoSmithKline AG
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus Stamm A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), Haemagglutininum influenzae A (H3N2) (Virus Stamm A/Darwin/9/2021 (H3N2)-like: reassortant virus IVR-227 derived from A/Darwin/6/2021), Haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant virus BVR-26 derived from B/Austria/1359417/2021 (Victoria lineage))
Unternehmen: GlaxoSmithKline AG
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Flucelvax Tetra, Injektionssuspension
Wirkstoffe: Haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), Haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), Haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))
Unternehmen: Medius AG
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Wirkstoffe: Haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), Haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), Haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))
Unternehmen: Medius AG
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Fluenz Tetra, Nasenspray, Suspension
Wirkstoffe: Virus influenzae A (H1N1) vivus attenuatum (Virus-Stamm A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Norway/31694/2022, MEDI 369815)), Virus influenzae A (H3N2) vivus attenuatum (Virus-Stamm A/Darwin/9/2021 (H3N2)-like (A/Norway/16606/2021 (MEDI 355293)), Virus influenzae B vivus attenuatum (Virus-Stamm B/Austria/1359417/2021-like: B/Austria/1359417/2021 (MEDI 355293, Victoria lineage))
Unternehmen: AstraZeneca AG
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Wirkstoffe: Virus influenzae A (H1N1) vivus attenuatum (Virus-Stamm A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Norway/31694/2022, MEDI 369815)), Virus influenzae A (H3N2) vivus attenuatum (Virus-Stamm A/Darwin/9/2021 (H3N2)-like (A/Norway/16606/2021 (MEDI 355293)), Virus influenzae B vivus attenuatum (Virus-Stamm B/Austria/1359417/2021-like: B/Austria/1359417/2021 (MEDI 355293, Victoria lineage))
Unternehmen: AstraZeneca AG
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Influvac Tetra 0.5 ml, Injektionssuspension
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus-Stamm A/Victoria/2570/2019 (H1N1)-pdm09: reassortant virus IVR-215 derived from A/Victoria/2570/2019), Haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Darwin/9/2021 (H3N2)-like: reassortant virus derived from A/Darwin/9/2021, SAN-010), Haemagglutininum influenzae B (Virus-Stamm B/Austria/1359417/2021 -like: reassortant virus BVR-26 derived from B/Austria/1359417/2021 (Victoria lineage))
Unternehmen: Viatris Pharma GmbH
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus-Stamm A/Victoria/2570/2019 (H1N1)-pdm09: reassortant virus IVR-215 derived from A/Victoria/2570/2019), Haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Darwin/9/2021 (H3N2)-like: reassortant virus derived from A/Darwin/9/2021, SAN-010), Haemagglutininum influenzae B (Virus-Stamm B/Austria/1359417/2021 -like: reassortant virus BVR-26 derived from B/Austria/1359417/2021 (Victoria lineage))
Unternehmen: Viatris Pharma GmbH
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
VaxigripTetra, Suspension pour injection dans une seringue pré-remplie
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), Haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/9/2021 (H3N2)-like: reassortant virus IVR-228 derived from A/Darwin/9/2021), Haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, Wilde type (Victoria lineage))
Unternehmen: Sanofi-Aventis (Suisse) SA
Abgabekategorie: B
Gruppe / Anwendung: Impfungen
Wirkstoffe: Haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022), Haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/9/2021 (H3N2)-like: reassortant virus IVR-228 derived from A/Darwin/9/2021), Haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, Wilde type (Victoria lineage))
Unternehmen: Sanofi-Aventis (Suisse) SA
Abgabekategorie: B
Gruppe / Anwendung: Impfungen